Trichothecene mycotoxins are recognized as highly bioactive compounds that can be used
in the design of new useful bioactive molecules. In Trichoderma brevicompactum, the first specific step
in trichothecene biosynthesis is carried out by a terpene cyclase, trichodiene synthase, that catalyzes
the conversion of farnesyl diphosphate to trichodiene and is encoded by the tri5 gene. Overexpression
of tri5 resulted in increased levels of trichodermin, a trichothecene-type toxin, which is a valuable
tool in preparing new molecules with a trichothecene skeleton. In this work, we developed the
hemisynthesis of trichodermin and trichodermol derivatives in order to evaluate their antimicrobial
and cytotoxic activities and to study the chemo-modulation of their bioactivity. Some derivatives with
a short chain at the C-4 position displayed selective antimicrobial activity against Candida albicans and
they showed MIC values similar to those displayed by trichodermin. It is important to highlight the
cytotoxic selectivity observed for compounds 9, 13, and 15, which presented average IC50 values of
2 g/mL and were cytotoxic against tumorigenic cell line MCF-7 (breast carcinoma) and not against
Fa2N4 (non-tumoral immortalized human hepatocytes)